Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2004

Open Access 01-12-2004 | Research

Melanoma-restricted genes

Authors: Ena Wang, Monica C Panelli, Katia Zavaglia, Susanna Mandruzzato, Nan Hu, Phil R Taylor, Barbara Seliger, Paola Zanovello, Ralph S Freedman, Francesco M Marincola

Published in: Journal of Translational Medicine | Issue 1/2004

Login to get access

Abstract

Human metastatic cutaneous melanoma has gained a well deserved reputation for its immune responsiveness. The reason(s) remain(s) unknown. We attempted previously to characterize several variables that may affect the relationship between tumor and host immune cells but, taken one at the time, none yielded a convincing explanation. With explorative purposes, high-throughput technology was applied here to portray transcriptional characteristics unique to metastatic cutaneous melanoma that may or may not be relevant to its immunogenic potential. Several functional signatures could be identified descriptive of immune or other biological functions. In addition, the transcriptional profile of metastatic melanoma was compared with that of primary renal cell cancers (RCC) identifying several genes co-coordinately expressed by the two tumor types. Since RCC is another immune responsive tumor, commonalities between RCC and melanoma may help untangle the enigma of their potential immune responsiveness. This purely descriptive study provides, therefore, a map for the investigation of metastatic melanoma in future clinical trials and at the same time may invite consideration of novel therapeutic targets.
Appendix
Available only for authorised users
Literature
1.
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1998, 17: 2105-2116.
2.
Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, Rubinstein L, Louie A, Mier JW, Gucalp R: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993, 11: 661-670.PubMed
3.
Wang E, Marincola FM: cDNA microarrays and the enigma of melanoma immune responsiveness. Cancer J Sci Am. 2001, 7: 16-23.
4.
Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA: Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol. 1992, 148: 638-643.PubMed
5.
Kawakami Y, Rosenberg SA: T-cell recognition of self peptides as tumor rejection antigens. Immunol Res. 1996, 15: 179-190.CrossRefPubMed
6.
Kawakami Y: Identification of human tumor antigens recognized by T-cells and their use for immunotherapy. Int J Hematol. 2003, 77: 427-434.CrossRefPubMed
7.
Paschen A, Eichmuller S, Schadendorf D: Identification of tumor antigens and T-cell epitopes, and its clinical application. Cancer Immunol Immunother. 2004, 53: 196-203. 10.1007/s00262-003-0479-3.CrossRefPubMed
8.
Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, White DE, Steinberg SM, Cole DJ, Kim HI: A randomized comparison of high dose and low dose intravenous interleukin-2 for the treatment of metastatic renal cell carcinoma. J Clin Oncol. 1994, 12: 1572-6.PubMed
9.
Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S: Tumors as elusive targets of T cell-directed immunotherapy. Trends Immunol. 2003, 24: 334-341. 10.1016/S1471-4906(03)00116-9.CrossRef
10.
Wang E, Miller LD, Ohnmacht GA, Mocellin S, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM: Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002, 62: 3581-3586.PubMedCentralPubMed
11.
Wang E, Lichtenfels R, Bukur J, Ngalame Y, Panelli MC, Seliger B, Marincola FM: Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res. 2004,
12.
Takashi M, Sakata T, Inaguma Y, Kato K: Elevated concentrations of gamma-enolase in renal cell tumors in rats: similarity to renal cell carcinoma in man. Urol Res. 1996, 24: 375-379. 10.1007/BF00389796.CrossRefPubMed
13.
Yaman O, Baltaci S, Arikan N, Ozdiler E, Gogus O, Muftuoglu YZ: Serum neuron specific enolase: can it be a tumour marker for renal cell carcinoma?. Int Urol Nephrol. 1996, 28: 207-210.CrossRefPubMed
14.
Gopalkrishnan RV, Sauane M, Fisher PB: Cytokine and tumor cell apoptosis inducing activity of mda-7/IL-24. Int Immunopharmacol. 2004, 4: 635-647. 10.1016/j.intimp.2004.01.015.CrossRefPubMed
15.
Quast T, Wehner S, Kirfel G, Jaeger K, De Luca M, Herzog V: sAPP as a regulator of dendrite motility and melanin release in epidermal melanocytes and melanoma cells. FASEB J. 2003, 17: 1739-1741.PubMed
16.
Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001, 19: 3477-3482.PubMed
17.
Powell DJ, Rosenberg SA: Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother. 2004, 27: 36-47. 10.1097/00002371-200401000-00004.PubMedCentralCrossRefPubMed
18.
Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, Chen Y, Bittner M, Strausberg RL, Riggins GJ, Wagner U, Kallioniemi OP, Trent JM, Morin PJ, Meltzer PS: Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene. 2004, 23: 2264-2274. 10.1038/sj.onc.1207337.CrossRefPubMed
19.
Boon K, Edwards JB, Siu IM, Olschner D, Eberhart CG, Marra MA, Strausberg RL, Riggins GJ: Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene. 2003, 22: 7687-7694. 10.1038/sj.onc.1207043.CrossRefPubMed
20.
Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M: The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res. 2004, 10: 4307-4313.CrossRefPubMed
21.
Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA: Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother. 1996, 19: 192-205.CrossRef
22.
Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM: Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer. 1999, 80: 781-790. 10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A.PubMedCentralCrossRefPubMed
23.
Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM: Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer. 1998, 75: 517-524. 10.1002/(SICI)1097-0215(19980209)75:4<517::AID-IJC5>3.3.CO;2-M.CrossRefPubMed
24.
Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL: Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother. 1998, 21: 27-31.CrossRefPubMed
25.
Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM: Short term kinetics of tumor antigen expression in response to vaccination. J Immunol. 2001, 167: 1809-1820.CrossRefPubMed
26.
Matsumoto K, Nakamura T: NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 2003, 94: 321-327.CrossRefPubMed
27.
Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, Klein HG, Marincola FM: Genetic profiling of peripharal mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol. 2002, 3: RESEARCH0035-10.1186/gb-2002-3-7-research0035.PubMedCentralCrossRefPubMed
28.
Monsurro' V, Wang E, Panelli MC, Nagorsen D, Jin P, Katia Z, Smith K, Ngalame Y, Even J, Marincola FM: Active-specific immunization against cancer: is the problem at the receiving end?. Sem Cancer Biol. 2003, 13: 473-480. 10.1016/j.semcancer.2003.09.011.CrossRef
29.
Monsurro VV, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, Nagorsen D, Connors M, Jacobson S, Marincola FM: Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood. 2004, 104: 1970-1978. 10.1182/blood-2004-02-0525.CrossRefPubMed
30.
Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ, Chapman HA, Shapiro SD, Elias JA: Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000, 106: 1081-1093.PubMedCentralCrossRefPubMed
31.
Croft M: Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 2003, 14: 265-273. 10.1016/S1359-6101(03)00025-X.CrossRefPubMed
32.
Robertson MJ: Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002, 71: 173-183.PubMed
33.
Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T: Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol. 2004, 24: 34-40. 10.1161/01.ATV.0000095360.62479.1F.CrossRefPubMed
34.
Collins M, Whitters MJ, Young DA: IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol Res. 2003, 28: 131-140. 10.1385/IR:28:2:131.CrossRefPubMed
35.
Parrish-Novak J, Foster DC, Holly RD, Clegg CH: Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol. 2002, 72: 856-863.PubMed
36.
Zhang L, Pagano JS: Structure and function of IRF-7. J Interferon Cytokine Res. 2002, 22: 95-101. 10.1089/107999002753452700.CrossRefPubMed
37.
Hiscott J, Grandvaux N, Sharma S, Tenoever BR, Servant MJ, Lin R: Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann N Y Acad Sci. 2003, 1010: 237-248. 10.1196/annals.1299.042.CrossRefPubMed
38.
Levy DE, Marie I, Smith E, Prakash A: Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J Interferon Cytokine Res. 2002, 22: 87-93. 10.1089/107999002753452692.CrossRefPubMed
39.
Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Reale M, Barbacane RC, Castellani ML, Mortari U, Boucher W, Letourneau R, Theoharides TC: Interleukin-16 network in inflammation and allergy. Allergy Asthma Proc. 2002, 23: 103-108.PubMed
40.
Okubo Y, Tsukadaira A, Takashi S, Kubo K, Koyama S: Chemotaxis of human CD4+ eosinophils. Int Arch Allergy Immunol. 2001, 125 (Suppl 1): 19-21. 10.1159/000053847.CrossRefPubMed
41.
Eichmuller S, Usener D, Jochim A, Schadendorf D: mRNA expression of tumor-associated antigens in melanoma tissues and cell lines. Exp Dermatol. 2002, 11: 292-301. 10.1034/j.1600-0625.2002.110402.x.CrossRefPubMed
42.
Harpio R, Einarsson R: S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem. 2004, 37: 512-518. 10.1016/j.clinbiochem.2004.05.012.CrossRefPubMed
43.
Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R: B-RAF is a therapeutic target in melanoma. Oncogene. 2004, 23: 6292-6298. 10.1038/sj.onc.1207785.CrossRefPubMed
44.
Steingrimsson E, Copeland NG, Jenkins NA: Melanocytes and the Microphthalmia Transcription Factor Network. Annu Rev Genet. 2004
45.
Kontochristopoulos GJ, Stavropoulos PG, Krasagakis K, Goerdt S, Zouboulis CC: Differentiation between merkel cell carcinoma and malignant melanoma: An immunohistochemical study. Dermatology. 2000, 201: 123-126. 10.1159/000018454.CrossRefPubMed
46.
Ramos-Vara JA, Beissenherz ME, Miller MA, Johnson GC, Pace LW, Fard A, Kottler SJ: Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol. 2000, 37: 597-608. 10.1354/vp.37-6-597.CrossRefPubMed
47.
Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J: High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun. 1999, 264: 751-758. 10.1006/bbrc.1999.1584.CrossRefPubMed
48.
Rumpler G, Becker B, Hafner C, McClelland M, Stolz W, Landthaler M, Schmitt R, Bosserhoff A, Vogt T: Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Exp Dermatol. 2003, 12: 761-771. 10.1111/j.0906-6705.2003.00082.x.CrossRefPubMed
49.
Repp AC, Mayhew ES, Apte S, Niederkorn JY: Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol. 2000, 165: 710-715.CrossRefPubMed
50.
Nyormoi O, Bar-Eli M: Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis. 2003, 20: 251-263. 10.1023/A:1022991302172.CrossRefPubMed
51.
Wang E, Miller L, Ohnmacht GA, Liu E, Marincola FM: High fidelity mRNA amplification for gene profiling using cDNA microarrays. Nature Biotech. 2000, 17: 457-459.
52.
Wang E, Marincola FM: Amplification of small quantities of mRNA for transcript analysis. In DNA arrays – A Molecular Cloning Manual. Edited by: Bowtell D, Sambrook J. 2002, Cold Springs Harbor, NY: Cold Spring Harbor Laboratory Press, 204-213.
53.
Feldman AL, Costouros NG, Wang E, Qian M, Marincola FM, Alexander HR, Libutti SK: Advantages of mRNA amplification for microarray analysis. Biotechniques. 2002, 33: 906-914.PubMed
54.
Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro V, Smith K, Hu N, Su H, Taylor PR, Marincola FM, Wang E: Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics. 2004, 13: 55-10.1186/1471-2164-5-55.CrossRef
55.
Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998, 95: 14863-14868. 10.1073/pnas.95.25.14863.PubMedCentralCrossRefPubMed
56.
Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO: Systematic variation in gene expression patterns in human cancer cell lines. Nature Genetics. 2000, 24: 227-235. 10.1038/73432.CrossRefPubMed
Metadata
Title
Melanoma-restricted genes
Authors
Ena Wang
Monica C Panelli
Katia Zavaglia
Susanna Mandruzzato
Nan Hu
Phil R Taylor
Barbara Seliger
Paola Zanovello
Ralph S Freedman
Francesco M Marincola
Publication date
01-12-2004
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2004
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-2-34

Other articles of this Issue 1/2004

Journal of Translational Medicine 1/2004 Go to the issue

Review

T-cell clonotypes in cancer

Research

Genetic polymorphisms of CYP2A13 and its relationship to nasopharyngeal carcinoma in the Cantonese population

Research

Evaluation of in vivo labelled dendritic cell migration in cancer patients

Research

Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors

Research

CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-ζ chain expression

Research

Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits